Connecticut is currently home to 1218 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787
Recruiting
The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
05/05/2025
Locations: University of Connecticut Health Center, Farmington, Connecticut
Conditions: Alzheimer Disease
Register for Updates
The Protrieve PROTECTOR Study
NCT06495996
Recruiting
The Protrieve PROTECTOR Study is a prospective, single-arm, multicenter study of the Protrieve Sheath.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Venous Thromboembolism, Deep Venous Thrombosis
Register for Updates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
NCT06495918
Recruiting
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age- Related Macular Degeneration
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/05/2025
Locations: Retina Consultants, P.C, Manchester, Connecticut
Conditions: Neovascular Age-related Macular Degeneration
Register for Updates
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06417775
Recruiting
A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. Menstrual migraine (MM) is defined as migraine attacks that occur within the perimenstrual period (PMP) in at least 2 out of 3 menstrual cycles. The PMP is from 2 days before the onset of menstrual bleeding to 2 days after. This study will assess how safe and effective ubrogepant i... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: New England Institute for Clinical Research /ID# 264019, Stamford, Connecticut
Conditions: Migraine
Register for Updates
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
NCT06328777
Recruiting
RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/05/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Systemic Sclerosis, Scleroderma
Register for Updates
Concurrent vs. Sequential Cessation of Dual Cigarette and E-cigarette Use
NCT06027840
Recruiting
The purpose of this research study is to understand whether concurrent treatment for cigarettes and e-cigarettes in which an individual quits both products at the same time (QUIT-C) or sequential treatment in which an individual quits cigarettes first followed by e-cigarettes is more effective for quitting both products. The study will also compare the effect of treatment on health-related biomarkers. All participants will receive varenicline, a medication used to treat tobacco use dependence, c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Cigarette Smoking, E-Cigarette Use, Smoking Cessation
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/05/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
05/05/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949
Recruiting
This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN012-0056. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study, 14-week CN012-0027 study or 14-week CN012-0056 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's Disease.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
05/05/2025
Locations: Local Institution - 1222, Farmington, Connecticut
Conditions: Psychosis Associated With Alzheimer's Disease
Register for Updates
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643
Recruiting
Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of SLE. This study is "double... Read More
Gender:
ALL
Ages:
Between 18 years and 63 years
Trial Updated:
05/05/2025
Locations: Yale University School of Medicine /ID# 254567, New Haven, Connecticut
Conditions: Systemic Lupus Erythematosus
Register for Updates
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT05617677
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/05/2025
Locations: Yale New Haven Hospital-Smilow Cancer Center, New Haven, Connecticut
Conditions: Systemic Lupus Erythematosus
Register for Updates
HEAL-IST IDE Trial
NCT05280093
Recruiting
Inappropriate Sinus Tachycardia (IST) is a prevalent and debilitating condition in otherwise healthy younger patients, resulting in significant loss of quality of life, lacking effective treatment options or systematic clinical evidence to support a therapy. The primary objective of this clinical trial is to evaluate the safety and effectiveness of a hybrid sinus node sparing ablation procedure for the treatment of symptomatic drug refractory or drug intolerant IST.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/05/2025
Locations: Saint Vincent's Medical Center, Bridgeport, Connecticut
Conditions: Inappropriate Sinus Tachycardia
Register for Updates